Semliki Forest virus-based immunotherapy for cancer

References

• Magee MS, Snook AE, Marszalowicz GP, et al. Immunotherapeutic strategies to target prognostic and predictive markers of cancer. Biomark Med. 2013;7:23–35.
   PubMed Web of Science ®Google Scholar
• Coley WB II. Contribution to the knowledge of Sarcoma. Ann Surg. 1891;14:199–220.
   PubMedGoogle Scholar
• Kozłowska A, Mackiewicz J, Mackiewicz A. Therapeutic gene modified cell based cancer vaccines. Gene. 2013;525:200–207.
   PubMed Web of Science ®Google Scholar
• Fortner RT, Damms-Machado A, Kaaks R. Systemic review: tumor-associated antigen autoantibodies and ovarian cancer early detection. Gynecol Oncol. 2017;147:465–480.
   PubMed Web of Science ®Google Scholar
• Muenst S, Läubli H, Soysal SD, et al. The immune system and cancer evasion strategies: therapeutic concepts. J Intern Med. 2016;279:541–562.
   PubMed Web of Science ®Google Scholar
• Seliger B, Ritz U, Ferrone S. Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer. 2006;118:129–138.
   PubMed Web of Science ®Google Scholar
• Bolhassani A, Safaiyan S, Rafati S. Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer. 2011;10:3.
   PubMed Web of Science ®Google Scholar
• Zajakina A, Spunde K, Lundstrom K. Application of alphaviral vectors for immunomodulation in cancer therapy. Curr Pharmaceut Design. 2017;23:1–27.
   PubMed Web of Science ®Google Scholar
• Strauss J, Strauss E. The alphaviruses: gene expression, replication and evolution. Microbiol Rev. 1994;58:491–562.
   PubMedGoogle Scholar
• Wang KS, Kuhn RJ, Strauss EG, et al. High-affinity laminin receptor is a receptor of Sindbis virus in mammalian cells. J Virol. 1992;66:4992–5001.
   PubMed Web of Science ®Google Scholar
• Mathiot CC, Grimaud G, Garry P, et al. An outbreak of human Semliki forest virus infection in Central African Republic. Am J Trop Med Hyg. 1990;42:386–393.
   PubMed Web of Science ®Google Scholar
• Niklasson B. Sindbis and Sindbis-like viruses. In: Monath TP, editor. The arboviruses: epidemiology and ecology. Boca Raton, FL: CRC Press, Inc.; 1988. p. 167–176.
   Google Scholar
• Rodrigues Faria N, Lourenço J, Marques de Cerqueira E, et al. Epidemiology of Chikungunya virus in Bahia, Brazil, 2014–2015. PLoS Curr. 2016 Feb 1;8. doi:10.1371/currents.outbreaks.c97507e3e48efb946401755d468c28b2.
   PubMedGoogle Scholar
• Liljestrom P, Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Bio/Technology. 1991;9:1356–1361.
   PubMed Web of Science ®Google Scholar
• Ehrengruber MU, Lundstrom K, Schweitzer C, et al. Recombinant Semliki Forest virus and Sindbis virus efficiently infect neurons in hippocampal slice cultures. Proc Natl Acad Sci USA. 1999;96:7041–7046.
   PubMed Web of Science ®Google Scholar
• Lundstrom K, Richards JG, Pink JR, et al. Efficient in vivo expression of a reporter gene in rat brain after injection of recombinant replication-deficient Semliki Forest virus. Gene Ther Mol Biol. 1999;3:15–23.
   Google Scholar
• Xiong C, Levis R, Shen P, et al. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science. 1989;243:1188–1191.
   PubMed Web of Science ®Google Scholar
• Davis NL, Brown KW, Johnston RE. In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant. Virology. 1989;171:189–204.
   PubMed Web of Science ®Google Scholar
• DiCiommo DP, Bremner R. Rapid, high level protein production using DNA-based Semliki Forest virus vectors. J Biol Chem. 1998;273:18060–18066.
   PubMed Web of Science ®Google Scholar
• Lundstrom K. New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy. Biol Targets Ther. 2018;12:43–60.
   PubMed Web of Science ®Google Scholar
• Lundstrom K. Alphavirus-based vaccines. Viruses. 2014;6:2392–2415.
   PubMed Web of Science ®Google Scholar
• Ying H, Zaks TZ, Wang RF, et al. Cancer therapy using a self-replicating RNA vaccine. Nat Med. 1999;5:823–827.
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Zullo SA, Tanaka R, et al. Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12. Neurosurg Focus. 2000;9:e7.
   PubMedGoogle Scholar
• Yamanaka R, Zullo SA, Tanaka R, et al. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J Neurosurg. 2001;94:474–481.
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Zullo SA, Ramsey J, et al. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. J Neurosurg. 2002;97:611–618.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Madoz JR, Prieto J, Smerdou C. Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol Ther. 2005;12:153–163.
   PubMed Web of Science ®Google Scholar
• Zajakina A, Vasilevska J, Kozlovska T, et al. Alphaviral vectors for cancer treatment. Vol. Chapter 28. Viral Nanotechnology. Boca Raton, USA: CRC Press, Taylor & Francis Group; 2015. p. 467–485.
   Google Scholar
• Rodriguez-Madoz JR, Zabala M, Alfaro M, et al. Short-term intratumoral interleukin-12 expressed from an alphaviral vector is sufficient to induce an efficient antitumoral response against spontaneous hepatocellular carcinomas. Hum Gene Ther. 2014;25:132–143.
   PubMed Web of Science ®Google Scholar
• Quetglas JI, Hervas-Stubbs S, Smerdou C. The immunological profile of tumor-bearing animals determines the outcome of cancer immunotherapy. Oncoimmunology. 2013;2:e24499.
   PubMed Web of Science ®Google Scholar
• Chikkanna-Gowda CP, McNally S, Sheahan BJ, et al. Inhibition of murine K-BALB and CT26 tumour growth using a Semliki Forest virus vector with enhanced expression of IL-18. Oncol Rep. 2006;16:713–719.
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Tsuchiya N, Yajima N, et al. Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. J Neurosurg. 2003;99:746–753.
   PubMed Web of Science ®Google Scholar
• Klimp AH, van der Vaart E, Lansink PO, et al. Activation of peritoneal cells upon in vivo transfection with a recombinant alphavirus expressing GM-CSF. Gene Ther. 2001;8:300–307.
   PubMed Web of Science ®Google Scholar
• Daemen T, Riezebos-Brilman A, Bungener L, et al. Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. Vaccine. 2003;21:1082–1088.
   PubMed Web of Science ®Google Scholar
• Walczak M, de Mare A, Riezebos-Brilman A, et al. Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine. Mol Pharm. 2011;8:65–77.
   PubMedGoogle Scholar
• Riezebos-Brilman A, Walczak M, Regts J, et al. A comparative study on the immunotherapeutic efficacy of recombinant semliki forest virus and adenovirus vector systems in a murine model for cervical cancer. Gene Ther. 2007;14:1695–1704.
   PubMed Web of Science ®Google Scholar
• van de Wall S, Walczak M, Rooij N, et al. Tattoo delivery of a Semliki Forest virus based vaccine encoding human papillomavirus E6 and E7. Vaccines (Basel). 2015;3:221–238.
   PubMed Web of Science ®Google Scholar
• Riezebos-Brilman A, Regts J, Chen M, et al. Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12. Vaccine. 2009;27:701–707.
   PubMed Web of Science ®Google Scholar
• Quetglas JI, Dubrot J, Bezunartea J, et al. Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol Ther. 2012;20:1664–1675.
   PubMed Web of Science ®Google Scholar
• Hsu KF, Hung CF, Cheng WF, et al. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther. 2001;8:376–383.
   PubMed Web of Science ®Google Scholar
• Van de Wall S, Ljungberg K, Ip PP, et al. Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens. Oncoimmunology. 2018;7:e1487913.
   PubMed Web of Science ®Google Scholar
• Lachman LB, Rao XM, Kremer RH, et al. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice. Cancer Gene Ther. 2001;8:259–268.
   PubMed Web of Science ®Google Scholar
• Yin X, Wang W, Zhu X, et al. Synergistic antitumor efficacy of combined DNA vaccines targeting tumor cells and angiogenesis. Biochem Biophys Res Comm. 2015;465:239–244.
   PubMed Web of Science ®Google Scholar
• Draghiciu O, Boerma A, Hoogeboom BN, et al. A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development. Oncoimmunology. 2015;4:e1029699.
   PubMed Web of Science ®Google Scholar
• Vähä-Koskela MJ, Kallio JP, Jansson LC, et al. Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice. Cancer Res. 2006;66:7185–7194.
   PubMed Web of Science ®Google Scholar
• Määttä AM, Liimatainen T, Wahlfors T, et al. Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models. Int J Cancer. 2007;121:863–870.
   PubMed Web of Science ®Google Scholar
• Heikkilä JE, Vähä-Koskela MJ, Ruotsalainen JJ, et al. Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice. PLoS One. 2010;5:e8603.
   PubMed Web of Science ®Google Scholar
• Ketola A, Hinkkanen A, Yongabi F, et al. Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma. Cancer Res. 2008;68:8342–8350.
   PubMed Web of Science ®Google Scholar
• Martikainen M, Ruotsalainen J, Tuomela J, et al. Oncolytic alphavirus SFV-VA efficiently eradicates subcutaneous and orthotopic human prostate tumours in mice. Br J Cancer. 2017;117:51–55.
   PubMed Web of Science ®Google Scholar
• Sanchez-Paulete AR, Teijeira A, Quetglas JI, et al. Intratumoral immunotherapy with XCL1 and SFLT3L encoded in recombinant Semliki Forest virus-derived vectors fosters dendritic cell-mediated T-cell cross-priming. Cancer Res. 2018;78:6643–6654.
   PubMed Web of Science ®Google Scholar
• Ballesteros-Briones MC, Martisova E, Casales E, et al. Short-term local expression of a PD-L1 blocking antibody from a self-replicating RNA vector induces potent antitumor responses. Mol Ther. 2019;27:1892–1905.
   PubMedGoogle Scholar
• Morse MA, Hobelka AC, Osada T, et al. An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Investig. 2010;120:3234–3241.
   PubMed Web of Science ®Google Scholar
• Slovin SF, Kehoe M, Durso R, et al. A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine. 2013;31:943–949.
   PubMed Web of Science ®Google Scholar
• Lundstrom K. Biology and application of alphaviruses in gene therapy. Gene Ther. 2005;12(Suppl. 1):S92–S97.
   PubMed Web of Science ®Google Scholar
• Ren H, Boulikas T, Lundstrom K, et al. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki Forest virus vector carrying the human interleukin-12 gene – A Phase I/II clinical trial. J Neurooncol. 2003;64:147–154.
   PubMed Web of Science ®Google Scholar
• Singh A, Koutsoumpli G, van de Wall S, et al. An alphavirus-based therapeutic vaccine: from design to clinical trial. Cancer Immunol Immunother. 2019;68:849–859.
   PubMed Web of Science ®Google Scholar
• Geall AJ, Verma A, Otten GR, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Soc USA. 2012;109:14604–14609.
   PubMed Web of Science ®Google Scholar
• Vogel AB, Lambert L, Kinnear E, et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol Ther. 2018;26:446–455.
   PubMed Web of Science ®Google Scholar
• Knudsen ML, Mbewe-Mvula A, Rosario M, et al. Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine. J Virol. 2012;86:4082–4090.
   PubMed Web of Science ®Google Scholar
• Erasmus JH, Khandhar AP, Guderian J, et al. A nanostructured lipid carrier for delivery of a replicating viral RNA provides single, low-dose protection against Zika. Mol Ther. 2018;26:2507–2522.
   PubMed Web of Science ®Google Scholar